Why This Overlooked Seattle Drugmaker Could be the Best Biotech Buy Right Now Post author:Sam Post published:November 28, 2017 Post category:BioPharma Omeros is getting a lot of love from investors and analysts these days. Source: BioSpace You Might Also Like Lilly's Cyramza Fails to Improve Overall Survival in Phase III Gastric Cancer Study December 10, 2017 Cancer Biotech Novocure Scores New $150M Debt Financing February 7, 2018 Exelixis Announces Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update February 27, 2017
Lilly's Cyramza Fails to Improve Overall Survival in Phase III Gastric Cancer Study December 10, 2017
Exelixis Announces Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update February 27, 2017
